Search results

748 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777

Proposed [GID-TA10810] Expected publication date: 22 October 2021

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: 10 August 2022

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lasmiditan for treating acute migraine [ID3759]

Proposed [GID-TA10807] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed